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INTRODUCTION:  The  prognosis  of anaplastic  thyroid  cancer  (ATC)  is poor  with  a mean  survival  time
of six  months  following  diagnosis.  Despite  various  attempts  to modify  common  treatment  modalities
including  surgery,  external  beam  radiation  and  chemotherapy,  an effective  treatment  is  not  available  yet.
We  report,  here,  a patient  who  achieved  long-term  survival  based  on multimodal  treatment,  including
in  vitro  evaluation  of drug response  of  his  tumor  cells.
PRESENTATION  OF  CASE:  A  42 years  old  male  patient  underwent  total  thyroidectomy  with  central  and
lateral  neck  dissection  for ATC  (pT4b,  pN0  (0/36),  L0, V0,  Pn1,  R0  cM0 – UICC-Stage:  IV b).  From  the  tumor
tissue  a primary  cell  culture  was  established.  While  the patient  received  a combined  radio-chemotherapy
cell  viability  assays  were  performed  using  Sorafenib,  Vandetanib  und  MLN8054  (Aurora  kinase  inhibitor)
as  inhibitors.  Cell  viability  was  determined  by  MTT-assay  after  72  and  144  h  of  treatment.
DISCUSSION:  All  the  three  compounds  affected  cell viability  in  a time-  and  dose dependent  manner.  These
effects  were  most  pronounced  by  Sorafenib.  Based  on  in  vitro ﬁndings,  the  patient  was  treated  daily  with
400  mg Sorafenib  for 75  days.  43  months  after  initial  diagnosis,  the  patient  had  no  evidence  of  disease  as
shown  by  MRI,  CT and  FDG-PET-CT  imaging.
CONCLUSION:  In  the setting  of  multimodal  treatment,  in  vitro  drug  evaluation  of individual  tumor  cells
of patients  might  be a promising  tool  to ameliorate  the fatal  prognosis  of  selected  ATC  patients.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Although anaplastic thyroid carcinoma (ATC) accounts only for
% of thyroid carcinomas, it is one of the most aggressive diseases
ith a median survival time of 6 months after the diagnosis and a
ortality rate higher than 90% [1]. Effective treatment strategies to
vercome this fatal prognosis are still lacking. Multimodality treat-
ent consisting of surgical resection, if possible, in combination
ith radio- and/or chemotherapy is generally recommended [2].
evertheless new therapeutic strategies are urgently required to
vercome the poor prognosis of ATC [3].
New insights into the biological behavior, the genetic and
olecular pathogenesis of ATC might offer the possibility of novel
argeted therapies [4].
∗ Corresponding author at: Department of Visceral, Thoracic and Vascular Surgery,
hilipps University Marburg, Baldingerstrasse, D-35043 Marburg, Germany.
E-mail address: seckhard@med.uni-marburg.de (S. Eckhardt).
ttp://dx.doi.org/10.1016/j.ijscr.2016.06.013
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
But as more new systemic agents become available, it is
important to get information on the drug response of different
compounds on individual ATC tumor cells.
Based on the current literature and on the results of our
own  investigations, three compounds (Aurora kinase inhibitor
MLN8054, multikinase inhibitors Vandetanib and Sorafenib) were
selected to be evaluated in this setting.
The BRAF- and multikinase inhibitor Sorafenib (Nexavar®,
BAY49-3006) has proven to inhibit multiple intracellular signal-
ing pathways leading to cell cycle arrest and initiation of apoptosis
in thyroid carcinoma cell lines regardless of their tumor subtype
origin or the BRAF-status [5]. Several studies evaluated the effect
of Sorafenib in thyroid cancer and reported positive effects [6,7].
Based on these results, Sorafenib got granted marketing autho-
rization since 2014 for the treatment of patients with progressive,
locally advanced or metastatic, differentiated thyroid carcinoma in
Europe.Vandetanib (AstraZeneca, Macclesﬁeld, UK) is an oral multiki-
nase inhibitor that selectively targets RET, VEGFR and EGFR tyrosine
kinases [8,9]. Its efﬁcacy was  determined in a phase II-trial enrolling
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
 –  OPEN  ACCESS
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Fig. 1. (A) Individual tumor cells established as primary culture. (B) Dose-response
curve of the tumor cells established as primary culture and treated with Sorafenib
for up to 144 h. Concentrations as indicated. Data reported present the mean ± SD
of  experiment performed in triplicates. Control: DMSO treated cells. (C) Dose-
response curve of the tumor cells established as primary culture and treated with
Sorafenib, Vandetanib and MLN8054 for 72 h. Concentrations as indicated. DataCASE  REPORT
S. Eckhardt et al. / International Journa
atients with poorly differentiated thyroid carcinoma (PDTC). It
as shown that patients receiving Vandetanib had longer progres-
ion free survival (PFS 11 months) compared to the placebo group
5 months) [10].
Aurora kinases (A–C) are serine/threonine kinases that play a
rucial role in cell division. They are overexpressed in many human
umors including ATC, where they account for aberrant cell prolif-
ration. MLN8054 has shown profound antitumor activity in ATC
ells in vitro and in vivo [11,12].
Here we report a patient suffering from ATC, who was free of
isease 43 months after multimodal treatment with surgery, radio-
hemotherapy and individualized targeted therapy with Sorafenib
ased on in vitro testing of drug efﬁcacy in his tumor cells. This
pproach might represent an effective strategy for an optimized,
ailored treatment of ATC.
. Presentation of case
A 42-year-old man  was referred to our institution in September
012, two weeks after he underwent a subtotal thyroidectomy in an
xternal hospital for a rapidly growing scintigraphically cold nod-
le in the right thyroid lobe. Histopathological examination stated
n ATC in the right lobe showing a negative staining for thyroid
ranscription factor 1 (TTF-1) and thyroglobulin (Tg). Postopera-
ive laryngoscopy demonstrated paresis of the laryngeal nerve on
he right side.
At this time, CT scan of the thorax, MRI  scan of the neck, thy-
oid scintigraphy and ultrasonography demonstrated a persisting
esion of 21 × 18 mm on the right side of the neck without evidence
f distant metastatic disease, but with some enlarged suspicious
ymph nodes (max. 26 × 20 mm).  Fine needle aspiration biopsy con-
rmed remnants of an ATC. Bronchoscopy and gastroscopy showed
o evidence of inﬁltration of the esophagus or the trachea.
After multidisciplinary tumor board decision, the patient
nderwent a multimodal therapeutic strategy, including an indi-
idualized targeted therapy.
The patient ﬁrst underwent completion thyroidectomy with
 bilateral cervicocentral and cervicolateral lymphadenectomy in
eptember 2012. The tumor was classiﬁed as ATC pT4b, pN0 (0/36),
0, V0, Pn1, R0 cM0  – UICC-Stage: IV b. A second expert conﬁrmed
he diagnosis of an ATC, immunonegative for TTF1 and TG and
ithout a BRAFV600E mutation. Ki-67 index was 60–70%. Four
eeks after surgical resection, a combined radio-chemotherapy
as started for four weeks with four cycles of Cisplatin 25 mg/m2
nd Docetaxel 20 mg/m2 combined with an external radiation
eam therapy for a total dose of 64.8 Gy. A MRI-scan, performed
fter receiving the combined therapy, was negative for metastases
r tumor recurrence.
From fresh tumor tissue a primary cell culture was  estab-
ished and in vitro analysis of three different drugs demonstrated
orafenib as the most effective one (Fig. 1A–C). Thus, Sorafenib was
dministered as an individual treatment strategy in off-label use
o the patient, with 400 mg  twice a day starting in January 2013.
ecause of adverse events (polyneuropathy, pain in muscles and
ones) the initial dose was reduced to 400 mg  once a day. Sorafenib
as given in three cycles over a period of 75 days.
After completion of multimodal treatment, the patient staging,
valuated by CT scan of the thorax and MRI  scan of the neck, showed
either recurrent disease nor metastases.
In June 2013, a complete re-staging, including MRI  of the neck,
T of the thorax and FDG-PET-CT, was performed. Imaging detected new solitary lesion of 10 × 7 mm size in the right upper lobe of
he lung that was suspicious for a metastasis (Fig. 2). According
o the recommendation of our tumor board, based on the absence
f additional lesions, the patient underwent a video-assisted tho-reported present the mean ± SD of experiment performed in triplicates. Control:
DMSO treated cells.
racoscopic wedge resection of this lesion. Histopathology of the
collected fresh tissue conﬁrmed the metastatic lesion originated
from the primary ATC. Collected tissue was  once again transferred
to the laboratory and established as a primary cell culture. The case
was discussed again in our interdisciplinary tumor board, where
an additional adjuvant therapy with taxans and platin was consid-
ered, but the patient refused this therapy and preferred to undergo
close surveillance with CT imaging of the thorax and MRI  of the
neck in 6 months intervals. At the last staging, in January 2016, 43
months after his initial operation, the patient was without evidence
of recurrent or metastatic disease.
2.1. Methods and experiments for individualized in-vitro testing
of drug efﬁcacy
2.1.1. Preparation of patient-derived human tumor tissue
Tumor cells were attained by mechanical dissociation of tumor
tissue, obtained from the completion thyroidectomy and the pul-
monary lesion and successfully established as primary cell culture.
2.1.2. Compounds
Sorafenib, Vandetanib and MLN8054 were used as inhibtors.
Stock solutions (10 mM each) were prepared in dimethylsulfoxid
(DMSO) and stored at −20 ◦C.
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.1.3. In vitro experiments
Primary cell culture was maintained by propagating the cells
n DMEM-h21/Ham’s F12 1:1 (v/v) supplemented with 10% FCS
nd 10U/ml penicillin and 100 g/ml streptomycin (all: Biochrom,
erlin, Germany) under standard conditions (37 ◦C, 5% CO2). Before
se in experiments, cell viability was assessed by Trypan blue exclu-
ion.
To test the sensitivity of the tumor cells towards the various
nhibitors, cells were seeded in 96 well plates (1 × 104 cells/well)
nd treated with increasing concentrations (0.1–10 M)  of
orafenib, Vandetanib und MLN8054 for up to 144 h. Cell viabil-
ty was determined by MTT-assay and dose-response curves were
reated.
.2. Results
Effects on cell viability of the individual tumor cells caused by
reatment with Sorafenib, Vandetanib and MLN8054.2.1. Cells established from the primary tumor
Cell viability of the individual tumor cells was considerably
ffected by all the three compounds. As documented here for
orafenib, each compound induced a dose- and time-dependentstasis of ATC nine months after diagnosis.
decrease in cell viability (Fig. 1B and C). This effect was most
pronounced by Sorafenib (Fig. 1B and C). Here cytoviability was
reduced to about 50% at a drug concentration about 2 M after 72 h,
whereas for Vandetanib and MLN8054 IC50 values were calculated
as ≈7 M and ≈5 M (Fig. 1B and C).
Prolonged treatment with 5 M Sorafenib and Vandetanib
resulted in 100% reduction of cell viability, MLN8054 showed a
lower effect, here cell viability was decreased only to about 30% at
10 M (Data not shown). Further, the effect of combined therapy
with Sorafenib and Vandetanib was evaluated in vitro. In compar-
ison with the single treatment, no synergistic effect or increase of
efﬁcacy could be measured (Data not shown).
2.2.2. Cells established from the pulmonary metastasis
Tumor cells originated from the pulmonary metastasis where
established as primary culture as well and treated with Sorafenib
and Vandetanib similarly. As assessed by MTT-assay, comparable
results were revealed. Once again after 72 h about 50% of the cells
were killed at concentrations about 3 M (Sorafenib) and 7 M
(Vandetanib), documenting a similar behaviour of the cells from
the primary tumor and the metastasis (Fig. 3A and B).
CASE  REPORT  –  O
S. Eckhardt et al. / International Journal of Su
Fig. 3. (A) Dose-response curves of tumor cells originated from the PT1 and the
Met2 and treated with Sorafenib for 72 h. Concentrations as indicated. Data reported
present the mean ± SD of experiment performed in triplicates. Control: DMSO
treated cells. (B) Dose-response curves of tumor cells originated from the PT1 and
the Met2 and treated with Vandetanib for 72 h. Concentrations as indicated. Data
reported present the mean ± SD of experiment performed in triplicates. Control:
DMSO treated cells.
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A. Wunderlich: analysis and interpretation of data, acquisitionPT = primary tumor.
Met  = pulmonary metastasis.
. Discussion
A generally accepted treatment strategy for ATC has not been
stablished yet [13,14]. By analyzing 2742 cases Haymart et al.
howed that the median survival of patients with stage IVb ATC
s quite poor with just 6 months. Despite of a prolonged overall
urvival (median survival of 9.9 month) obtained by a com-
ined multidisciplinary therapy consisting of surgery, radiation and
hemotherapy, there is still a desperate need to support and accel-
rate clinical research [15].
In previous publications several authors pointed out the bene-
t of an initial complete and radical resection of the ATC [16,17].
assler et al. showed that patients without tumor residues (R0)
ad a signiﬁcantly better prognosis with a median survival of 6.1
onths than patients with tumor residues (R1/R2) with a median
urvival of 2.2 months and a 3-year survival of 50% vs.  4%. There-
ore, in our case we performed a radical completion thyroidectomy
ith bilateral neck dissection to achieve a R0 situation.
Although several reports pointed out the inefﬁcacy of single
hemotherapy in patients with ATC [18,19], some combined ther-
pies improved survival [20]. That is why our patient received
 corresponding to the American Thyroid Association Guidelines
or Patients with Anaplastic Thyroid Carcinoma – a combined
hemotherapy with docetaxel and cisplatin [4]. Both agents are
nown to have a great clinical activity in metastatic ATC, but it is
ot conﬁrmed that they really prolonged survival or quality of life
4]. So, to complete the multimodal treatment strategy in the pre-
ented patient, surgical resection and chemotherapy were followed
y radiation therapy. Retrospective analysis of the SEER data of 516
atients revealed that only the combined use of surgical resection
nd external beam radiotherapy were identiﬁed as independent
redictors of survival in ATC patients [1].PEN  ACCESS
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Our patient ﬁrst received a combined radio-chemotherapy.
Meanwhile a primary cell culture was established and the effects
of two multi-kinase inhibitors (Sorafenib, Vandetanib) and of one
aurora kinase inhibitor (MLN8054) were evaluated in vitro. From
these the mostly effective one was  Sorafenib. Further, similar
effects were shown for cells of the primary tumor and the metas-
tasis. These results point out the feasibility of preclinical in vitro
evaluation, especially, since it is well known, that the biological
behavior of ATC – like other tumors – is inconsistent. Therefore a
successful therapy may  be more common, if the patient receives –
corresponding to the individual evaluated ATC – the most effective
treatment.
As younger age is associated with improved survival in patients
affected by ATC [15], it must be pointed out that the positive clinical
course in the presented case might have been also promoted by the
limited disease at the time of diagnosis and the young age of the
patient.
4. Conclusion
Our case report demonstrates – to our best knowledge – for the
ﬁrst time that pre-therapeutic in vitro investigation of novel drugs
could succeed for a personalized antitumor therapy in a patient
affected by ATC. By availability of vital tumor cells, this approach
might offer the possibility for reﬂection of the individual tumor
cell characteristics and optimize therapeutic options for patients
suffering from ATC.
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